Phase 3 Study of T-DXd and Rilvegostomig versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Trial Identifier: D781PC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Start Date: June 2024
Primary Completion Date: April 2028
Study Completion Date: March 2029
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Linz, AT, 4010
AT Salzburg, AT, 5020
AT Wien, AT, 1090
AT Wiener Neustadt, AT, 2700
BE Anderlecht, BE, 1070
BE Edegem, BE, 2650
BE Leuven, BE, 3000
BE Liège, BE, 4000
BE Roeselare, BE, 8800
BR Porto Alegre, BR, 90035-000
BR Sao Paulo, BR, 01246-000
CA, NS Halifax, NS, CA, B3H 1V7
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3A 1A1
DE Berlin, DE, 13353
DE Dresden, DE, 01370
DE Frankfurt, DE, 60488
DE Göttingen, DE, 37075
DE Hamburg, DE, 22763
DE Köln, DE, 50937
DE Leipzig, DE, 4103
DE Lübeck, DE, 23538
DE Munchen, DE, 81377, DE
DE Ulm, DE, 89081
DE Wuerzburg, DE, 97080
JP Kashiwa, JP, 227-8577
JP Koto-ku, JP, 135-8550
JP Osaka-shi, JP, 541-8567
JP Suita-city, JP, 565-0871
JP Yokohama-shi, JP, 241-8515
KR Seoul, KR, 03080
NL ROTTERDAM, NL, 3015 GD
TW Kaohsiung, TW, 833
TW Taipei, TW, 112
TW Taipei, TW, 10002
TW Taoyuan, TW, 333